Where is the Indian Pharma industry heading?

Updated on July 2, 2015 in Pharma
2 on March 18, 2015

Is there a growth of the pharma sector in India? Considering the various issues the industry is facing, the future does not look bright. While on the one hand some key domestic players are selling their core brands to overseas buyers or to some domestic based MNCs and looking at investing in research and development, there are several issues that are causing a bit of anxiety.

Starting with the clinical trial activities, USFDA’s stringent measures on the domestic generic drug makers, and regulation of National Pharmaceutical Pricing Policy affecting both the domestic and multinationals in India, some of the key players have begun exiting the area.  The current regulatory restrictions on the clinical trial front has resulted in many of the leading MNC pharma players to wind up operations and shift the activity to other countries.

  • Liked by
Reply

Indian Pharma Industries are not big players in new drug discovery clinical trials and are more into generic drugs and are not affected by the new regulations for conducting clinical trials, it is the MNCs who are the major players and the ones who invest big money in new drug discovery and reap the benefits by branding, patents and monopolizing. and are always looking for countries with easy regulatory requirements.The Govt of India’s policy of providing health services to the poor, and the rural population cannot support the MNCs who are only looking for profits.

on July 2, 2015

LSW has been in the forefront in building a bridge between the Industry and the Regulators and have hosted a conference ‘ clinical Research-Regulatory Norms-Current Challenges and the Future of Pharma Industry in India’ between the DCGI and the Industry for the first time. This has been followed up by two Round Table Meetings, one with Prof.Dr.Ranjit Roy Chaudhury and Industry Heads and the second Round Table between the Jt.Secretary, Min of Health & Family Planning, Dr. Ranjit Roy Chaudhury,DCGI , the Industry Heads,CROs and Other stake holders in Clinical trials.The meetings were well attended and  frank discussions took place between the Regulatory authorities and the Industry and other stake holders.The  Ministry of Health & Family Planning represented by Mr. K.L.Sharma, Joint Secretary and the DCGI have assured that speedy action will be taken to put the clinical trial operations back on track , implementing the Supreme Court’s directives and the Dr. Ranjit Roy Chaudhury Report Recommendations.
LSW will continue to provide a platform to the Pharma/ Biotech industries to air their problems through the LSW Forum..

Show more replies
  • Liked by
Reply
Cancel